Longest median OS in the NSCLC and RCC cohorts correlated with anti‐PD‐1 + anti‐CTLA‐4 therapy (19.20 [10.30–NR] and 30.80 [26.50–NR] months). This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.